Latest Cancer TreatmentsDr. Mohammadreza Dabiri
Dr. Mohammadreza Dabiriفارسی
Treatment regimen

TC regimen (docetaxel and cyclophosphamide): dose and schedule

Anthracycline-free adjuvant treatment of breast cancer, every 21 days

Updated: 28 October 20261 min read1 reference

Summary for doctors

  • An anthracycline-free alternative in early breast cancer, especially when cardiac risk matters [1].
  • 4 cycles every 21 days [1].
  • In practice, febrile neutropenia is more common than in the original study; consider G-CSF prophylaxis.

Dose and schedule

TC

Early breast cancer, adjuvantCycle length: Every 21 days

Early breast cancer, adjuvant

DrugDoseRouteSchedule
Docetaxel75 mg/m²IV over 1 hourDay 1
Cyclophosphamide600 mg/m²IVDay 1
Cycle length
Every 21 days
Duration
4 cycles

Doses as in US Oncology 9735 [1].

Doses follow the trial protocol, guideline or official drug label (source given in the notes of each regimen). Before prescribing, check blood counts, renal and hepatic function, drug interactions and the patient’s condition, and adjust the dose according to the drug label.

Premedication and supportive care

  • Docetaxel premedication: dexamethasone 8 mg twice a day for 3 days starting the day before the infusion (for fluid retention and hypersensitivity).
  • Antiemetics: moderate emetogenicity (5-HT3 and dexamethasone).
  • G-CSF: many centres give primary prophylaxis, especially in older patients (G-CSF tool).

Monitoring and dose adjustment

  • Blood counts before each cycle; liver enzymes (docetaxel is more toxic with a raised bilirubin, or AST/ALT above 1.5 × with alkaline phosphatase above 2.5 ×).
  • Febrile neutropenia or prolonged neutropenia: docetaxel 60 to 65 mg/m², or G-CSF.

Main evidence

Show detailsHide

US Oncology 9735: after 7 years, TC gave better disease-free survival (81% vs 75%) and overall survival (87% vs 82%) than AC [1].

Related cancer types

Breast cancer

Treatment regimens (physicians)

AC followed by paclitaxel (dose-dense and weekly)TCHP regimen: dose and schedule in HER2-positive breast cancerWeekly paclitaxel with trastuzumab (APT regimen)KEYNOTE-522 regimen: pembrolizumab and chemotherapy in triple-negative breast cancerTrastuzumab emtansine (T-DM1, Kadcyla): dose and scheduleTrastuzumab deruxtecan (T-DXd, Enhertu): dose and monitoringAdjuvant capecitabine after neoadjuvant treatment (CREATE-X)Sacituzumab govitecan (Trodelvy)Pembrolizumab with chemotherapy in metastatic triple-negative breast cancer (KEYNOTE-355)

Physician tools and lessons

Cumulative Anthracycline Dose and Doxorubicin Equivalents10 cheap steps that save patients' livesBone-modifying agents in cancer: bone metastases, adjuvant use and osteonecrosis of the jawGermline genetic testing in cancer: who, and which genes?Management of brain metastasesFertility preservation before cancer treatmentMalignant pleural effusion: drainage, pleurodesis or an indwelling catheterCancer during pregnancy: chemotherapy and decisions

References

1 reference
Show all referencesClose the reference list

Numbers in the text, such as [1], refer to these sources. Sources with a “Study card” button are summarised in the site’s evidence library.

  1. 1
    Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735Jones S, Holmes FA, O'Shaughnessy J, et al · J Clin Oncol · 2009;27:1177-83
    DOIPubMed Back to text: 1 2 3 4

This page is based on reputable scientific sources and was last updated on 28 October 2026. The content of this website is for educational and informational purposes only and does not replace consultation, diagnosis or treatment by a specialist physician. Consult your treating physician about any treatment decision.

Printed from the website; the full and up-to-date version: https://drdabiri.com/en/regimens/docetaxel-cyclophosphamide-tc/

Related pages

27 October 2026 FOLFOX (mFOLFOX6): dose, schedule and side effects Dose and schedule of mFOLFOX6 (oxaliplatin 85, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), length of adjuvant treatment, premedication, neuropathy and dose adjustment. 27 October 2026 CAPOX (XELOX): dose, schedule and side effects Dose and schedule of CAPOX or XELOX (oxaliplatin 130 and capecitabine 1000 twice daily, days 1 to 14), length of adjuvant treatment, renal adjustment and side effects. 27 October 2026 FOLFIRI regimen: dose, schedule and side effects Dose and schedule of FOLFIRI (irinotecan 180, leucovorin 400, fluorouracil 400 bolus and 2400 as a 46-hour infusion), diarrhoea control, UGT1A1 and dose adjustment.